{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:28:37Z","timestamp":1755692917603,"version":"3.40.5"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oritavancin and dalbavancin are long\u2010acting lipoglycopeptides with activity against susceptible gram\u2010positive bacteria, including methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic>. Though similar in structure to traditional glycopeptide antibiotics like vancomycin, these antibiotics have terminal half\u2010lives &gt;10 days, and, as a result, there is potential for administration of vancomycin to a patient while oritavancin or dalbavancin are still appreciably present in serum. Given the structural similarities, this creates an opportunity for lab assay interference when performing therapeutic drug monitoring for vancomycin. Following higher\u2010than\u2010expected serum vancomycin concentrations in a patient who received both oritavancin and vancomycin within a short time frame, we evaluated the potential for lipoglycopeptide interference with clinical vancomycin assays. Five platforms covering 3 immunoassay technologies were used to quantify vancomycin concentrations in serum spiked with oritavancin or dalbavancin. Oritavancin generated spurious vancomycin concentrations (20%\u201084% increase) in both enzyme\u2010multiplied immunoassay technique and a particle\u2010enhanced turbidimetric inhibition immunoassay. However, the improper detection of oritavancin was not consistent across all particle\u2010enhanced turbidimetric inhibition immunoassay platforms. Dalbavancin interference was not detected on any of the platforms tested. The interference from oritavancin may result in falsely elevated vancomycin concentrations and, subsequently, inappropriately adjusted vancomycin doses.<\/jats:p>","DOI":"10.1002\/jcph.1975","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T11:38:50Z","timestamp":1632656330000},"page":"472-478","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long\u2010Acting Lipoglycopeptides Can Interfere With Vancomycin Therapeutic Drug Monitoring"],"prefix":"10.1002","volume":"62","author":[{"given":"Dan F.","family":"Smelter","sequence":"first","affiliation":[{"name":"School of Pharmacy University of Wisconsin\u2010Madison  Madison Wisconsin USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Trisler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Pittsburgh Medical Center Shadyside  Pittsburgh Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin K.","family":"McCreary","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Department of Medicine University of Pittsburgh School of Medicine  Pittsburgh Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Pittsburgh Medical Center Shadyside  Pittsburgh Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Copeland","sequence":"additional","affiliation":[{"name":"ACL Laboratories Advocate Aurora Health  Milwaukee Wisconsin USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Dilworth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Advocate Aurora Health St. Luke's Medical Center  Milwaukee Wisconsin USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5012-5993","authenticated-orcid":false,"given":"Warren E.","family":"Rose","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Wisconsin\u2010Madison  Madison Wisconsin USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1198-743X(16)30095-7"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu778"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz162"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1354"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.9.702.31548"},{"issue":"1","key":"e_1_2_9_8_1","first-page":"9","article-title":"Falsely elevated vancomycin\u2010concentration values from enzyme immunoassay leading to treatment failure","volume":"77","author":"Singer B","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03785-14"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/11534440-000000000-00000"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-020-00188-6"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00231-09"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0340-4"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2003.tb00628.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir920"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki005"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0077-7"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(93)90125-Q"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000043"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1974972"},{"key":"e_1_2_9_21_1","unstructured":"e\u2010LAB Solutions Suite.College of American Pathologists.https:\/\/www.cap.org\/laboratory\u2010improvement\/proficiency\u2010testing\/e\u2010lab\u2010solutions\u2010suite. Accessed September 21 2021."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06050-1"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02663-14"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12620-z"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01968-16","article-title":"Effects of oritavancin on coagulation tests in the clinical laboratory","volume":"61","author":"Belley A","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R566"},{"issue":"9","key":"e_1_2_9_27_1","first-page":"1527","article-title":"Undetectable vancomycin concentrations utilizing a particle enhanced turbidimetric inhibition immunoassay in a patient with an elevated IgM level","volume":"63","author":"Cooper AA","year":"2017","journal-title":"Clin Lab"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2279"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19130"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2057"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1975","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.1975","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T13:53:04Z","timestamp":1693144384000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/jcph.1975"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1975","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"2021-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}